Astria Therapeutics Announces Publication Of STAR-0215 Preclinical Data In The Journal Of Pharmacology And Experimental Therapeutics
Portfolio Pulse from Happy Mohamed
Astria Therapeutics, Inc. (NASDAQ:ATXS) has announced the publication of preclinical data for STAR-0215, a potential long-acting therapy for hereditary angioedema (HAE), in the Journal of Pharmacology and Experimental Therapeutics. The data supports STAR-0215's profile as a potent plasma kallikrein inhibitor with a long half-life. Initial results from a Phase 1a trial support STAR-0215's target profile, with final results expected in Q4 2023. The Phase 1b/2 ALPHA-STAR trial is ongoing, with initial results expected in mid-2024.
August 31, 2023 | 12:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Astria Therapeutics' preclinical data for STAR-0215, a potential long-acting therapy for HAE, has been published. This could potentially boost investor confidence in the company's research and development capabilities.
The publication of preclinical data for Astria Therapeutics' STAR-0215 in a reputable journal validates the company's research and could potentially boost investor confidence. The ongoing Phase 1b/2 trial and the expected results in mid-2024 could further impact the company's stock positively if the results are favorable.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100